The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells

Journal of Cellular Physiology

Volumn 222, Issue 2, 2010, Pages 282-285

  Kumano, Keiki ^a   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN EVI 1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EVI1 PROTEIN, HUMAN; EVI1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ADULT; CELL LEVEL; EMBRYO DEVELOPMENT; GENE DELETION; GENE OVEREXPRESSION; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROVIRUS; SHORT SURVEY; ADULT STEM CELL; ANIMAL; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; EMBRYONIC STEM CELL; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; METABOLISM; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

ADULT; ADULT STEM CELLS; ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; PROTO-ONCOGENES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 73349130011     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21953     Document Type: Short Survey

References (51)

1. Adamo L, Naveiras O, Wenzel PL, McKinney-Freeman S, Mack PJ, Gracia-Sancho J, Suchy-Dicey A, Yoshimoto M, Lensch MW, Yoder MC, García-Cardeña G, Daley GQ. 2009. Biomechanical forces promote embryonic hematopoiesis. Nature 459:1131-1135.
2. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R. 2003. High EV11 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 101:837-845.
3. Bordereaux D, Fichelson S, Tambourin P, Gisselbrecht S. 1990. Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs. Oncogene 5:925-927.
4. Burns CE, Traver D, Mayhall E, Shepard JL, Zon LI. 2005. Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev 19:2331-2342.
5. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, Kim HJ, Sellers S, Hematti P, Schmidt M, von Kalle C, Akagi K, Donahue RE, Dunbar CE. 2005. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106:2530-2533.
6. Cumano A, Dieterlen-Lievre F, Godin I. 1996. Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86:907-916. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA. 2002. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22:5506-5517.
7. Delassus S, Cumano A. 1996. Circulation of hematopoietic progenitors in the mouse embryo. Immunity 4:97-106.
8. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. 1993. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 13:4291-4300.
9. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. 1996. Intergenic splicing of MDS1 and EV11 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 93:1642-1647.
10. Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. 2004. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci USA 101:15184-15189.
11. Gering M, Patient R. 2005. Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos. Dev Cell 8:389-400.
12. Godin I, Dieterlen-Lievre F, Cumano A. 1995. Emergence of multipotent hemopoietic cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5 days postcoitus. Proc Natl Acad Sci USA 92:773-777.
13. Goyama S, Yamaguchi Y, Imai Y, Kawazu M, Nakagawa M, Asai T, Kumano K, Mitani K, Ogawa S, Chiba S, Kurokawa M, Hirai H. 2004. The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. Blood 104:3558-3564.
14. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S, Kurokawa M. 2008. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3:207-220.
15. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, Rowan R, Curley DP, Kutok JL, Akashi K, Williams IR, Speck NA, Gilliland DG. 2005. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106:494-504.
16. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63-74.
17. Hirai H. 1999. The transcription factor Evi-1. Int J Biochem Cell Biol 31:1367-1371.
18. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN, Mucenski ML. 1997. The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 65:55-70.
19. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Ogawa S, Kurokawa M, Hirai H. 2004. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10:299-304.
20. Ichikawa M, Goyama S, Asai T, Kawazu M, Nakagawa M, Takeshita M, Chiba S, Ogawa S, Kurokawa M. 2008. AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol 180:4402-4408.
21. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H. 2000. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96:3154-3160.
22. Kustikova O, Fehse B, Modlich U, Yang M, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B, Li Z, Baum C. 2005. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308:1171-1174.
23. Li Z, Chen MJ, Stacy T, Speck NA. 2006. Runx1 function in hematopoiesis is required in cells that express Tek. Blood 107:106-110.
24. Medvinsky AL, Dzierzak EA. 1996. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86:897-906.
25. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88:10431-10434.
26. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HCIII, Jenkins NA, Copeland NG. 1988. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 8:301-308.
27. Muller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. 1994. Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1:291-301.
28. Nakagawa M, Ichikawa M, Kumano K, Goyama S, Kawazu M, Asai T, Ogawa S, Kurokawa M, Chiba S. 2006. AML1/Runx1 rescues Notch1-null mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis. Blood 108:3329-3334.
29. Nitta E, Izutsu K, Yamaguchi Y, Imai Y, Ogawa S, Chiba S, Kurokawa M, Hirai H. 2005. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene 24:6165-6173.
30. North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, Robin C, Binder M, Dzierzak E, Speck NA. 2002. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 16:661-672.
31. Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, Hangaishi A, Tanaka K, Matsuo Y, Minowada J, Tsubota T, Yazaki Y, Hirai H. 1996. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 13:183-191.
32. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
33. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y. 1999. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 93:1817-1824.
34. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EV11, PRDM16 or SETBP1. Nat Med 12:401-409.
35. Perkins AS, Fishel R, Jenkins NA, Copeland NG. 1991. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 11:2665-2674.
36. Pintado T, Ferro MT, San Román C, Mayayo M, Laraña JG. 1985. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55:535-541.
37. Robin C, Ottersbach K, Durand C, Peeters M, Vanes L, Tybulewicz V, Dzierzak E. 2006. An unexpected role for IL-3 in the embryonic development of hematopoietic stem cells. Dev Cell 11:171-180.
38. Samokhvalov IM, Samokhvalova NI, Nishikawa S. 2007. Cell tracing shows the contribution of the yolk sac to adult haematopoiesis. Nature 446:1056-1061.
39. Sato T, Goyama S, Nitta E, Takeshita M, Yoshimi M, Nakagawa M, Kawazu M, Ichikawa M, Kurokawa M. 2008. Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-b signaling. Cancer Sci 99:1407-1413.
40. Schwieger M, Löhler J, Friel J, Scheller M, Horak I, Stocking C. 2002. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 196:1227-1240.
41. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. 2007. Repression of RUNXI activity by EV II: A new role of EVII in leukemogenesis. Cancer Res 67:5658-5666.
42. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopeniawith propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175.
43. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. 1999. MDS1/EVII enhances TGF-beta I signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AMLI/MDSI/EVII, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta I. Leukemia 13:348-357.
44. Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J. 1994. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EV11 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 84:2681-2688.
45. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111:621-633.
46. Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto M, Enver T. 2007. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med 4:e172.
47. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628.
48. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93:3444-3449.
49. Wilkinson RN, Pouget C, Gering M, Russell AJ, Davies SG, Kimelman D, Patient R. 2009. Hedgehog and Bmp polarize hematopoietic stem cell emergence in the zebrafish dorsal aorta. Dev Cell 16:909-916.
50. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE. 2001. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98:10398-10403.
51. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K. 2005. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24:1976-1987.